Inactive Instrument

News Relmada Therapeutics Inc OTC Bulletin Board

Equities

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Mar. 19	Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Mar. 19	Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 20	AQ
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024	Mar. 12	PR
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	Mar. 05	PR
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	Jan. 04	MT
Relmada Therapeutics Provides Corporate Update	Jan. 04	PR
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	Jan. 03	CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023	Nov. 03	PR
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease	23-10-11	MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023	23-10-11	CI
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit	23-10-10	AQ
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress	23-10-09	AQ
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit	23-10-09	PR
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress	23-10-06	PR
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder	23-09-20	PR
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index	23-09-18	CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	23-09-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Relmada Therapeutics Inc OTC Bulletin Board

Equities

Summary

Filters